Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Bumetanide
Leo Laboratories Limited
C03CA; C03CA02
Bumetanide
1 milligram(s)
Tablet
Product subject to prescription which may be renewed (B)
Sulfonamides, plain; bumetanide
Marketed
1978-04-01
INS007-01: 190 × 250 mm - Page 1 of 2 0 5 7 1 9 4 PACKAGE LEAFLET: INFORMATION FOR THE USER BURINEX ® 1 MG TABLETS bumetanide READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. • In this leaflet Burinex ® 1 mg Tablets will be called Burinex. WHAT IS IN THIS LEAFLET 1. What Burinex ® is and what it is used for 2. What you need to know before you take Burinex ® 3. How to take Burinex ® 4. Possible side effects 5. How to store Burinex ® 6. Contents of the pack and other information 1. WHAT BURINEX ® IS AND WHAT IT IS USED FOR Burinex 1 mg tablets contain the active substance bumetanide. It is a diuretic (water tablet). It works by removing any excess water from your body. It will make you go to the toilet more often. Burinex is used in adults to treat oedema which occurs as a result of heart, kidney or liver problems. Oedema means that there is too much water in parts of your body. Oedema can cause symptoms such as swollen ankles or trouble breathing. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE BURINEX ® DO NOT TAKE BURINEX • If you are allergic (hypersensitive) to bumetanide or any of the other ingredients in this medicine (listed in section 6). • If you have been told that you have very low levels of potassium, sodium or chloride in your blood. • If you cannot pass water (urine) at all. • If you have severe liver problems or are in a coma caused by this (hepatic encephalopathy). WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taking Burinex • If you have severe liver problems. • If you Read the complete document
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Burinex 1 mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 1 mg of Bumetanide. Excipient with known effect: Each tablet contains 52.3 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet A white, flat, circular, uncoated scored tablet marked with the number 133 on the scored face and an Assyrian lion on the reverse. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Burinex 1 mg Tablets are indicated in adults in the management of oedema due to congestive heart failure, hepatic cirrhosis and renal disease, including nephrotic syndrome. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The usual daily dosage is 0.5 to 2 mg as a single or divided dose. The dosage may be increased if necessary and should be carefully adjusted according to patient response. _Paediatric population_ The medicinal product is not recommended for children as there is limited information on safety, efficacy and dosage in children. _Elderly_ The dosage recommendations for adults apply, but in the elderly bumetanide is generally eliminated more slowly. Dosage should be titrated until the required response is achieved. Patients with liver or renal insufficiency Depending on the liver or renal function, the dose should be titrated according to the patient’s response and required therapeutic effect (see section 4.4). Method of administration For oral administration. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ __ Read the complete document